Recent

% | $
Quotes you view appear here for quick access.

Impax Laboratories Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pere_joseph pere_joseph Oct 31, 2012 10:31 AM Flag

    Mylan is seeking at 3-4 billion purchase in generic space and also seeking Proprietary addions= IPXL

    Well probably not today. The earnings miss is considerable. Bought in because of the expected increase in revenues and new product. As so often is the case, one has to be patient;

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • No deal for foreseeable future. Larry has all the money he needs and wants to see how far this company can go on its own. With Rytary approval, this stock can grow in leaps and bounds. Several other branded products on the slate through acquisitions. This drop after earnings is a gift for the LT investor of IPXL.

      Sentiment: Strong Buy

      • 2 Replies to tanis2476
      • You are right on Tanis. I bought more this morning. This is a great company and I agree- let it run.

        Sentiment: Strong Buy

      • I agree on your sentiment but Teva has to be the Lion licking its chops as they need to close the immediate and forseable gap on Parkinsons competition. I have studied and learned that Rytary is the most effective Parkinson's medication coming to market.

        Teva may just step in and swallow hole Impax as they are partners on many other fronts. Larry is wealthy, but greed is greed and a stock swap with Teva would be too hard to pass up.

 
IPXL
48.46+0.10(+0.21%)Jul 31 3:59 PMEDT